Oxford resumed testing of its coronavirus vaccine

Photos: Along with Air Force One, inside cars, Covid-19 marks the US electoral campaign

23.10.2020 - 06: 42hIf the coronavirus was already marking the electoral campaign of the Elections in the United States, the contagion of President Donald...

Less chaotic bickering and more content in Trump and Biden’s second debate

The second election debate between US President Donald Trump and his Democratic rival Joe Biden on the night from Wednesday to Thursday was a...

The 20 most outstanding phrases of the last presidential debate between Donald Trump and Joe Biden in the United States

Health policies and accusations of corruption were the moments of greatest tension between the Republican and Democratic candidates.Donald Trump and Joe Biden starred in...

Man accused of sexually abusing 112 girls online

The Australian Police on Friday accused a 25-year-old man of Internet sexual abuse of 112 girls around the world whom he blackmailed into...

Perspective: Joe Biden already slipped the presidential laugh

That seemed almost civilized. Donald Trump and Joe Biden may not have restored faith in the political debate culture, but the duo’s last...

This was officially reported by the English university after the pause they took due to an adverse reaction from a volunteer. It is the vaccine that will be produced in Argentina.

The English University of Oxford reported on Saturday that it resumed clinical trials of the coronavirus vaccine, after being recently interrupted after a volunteer in the United Kingdom suffered an adverse reaction.

“Clinical Trials for the AstraZeneca Oxford Coronavirus Vaccine, AZD1222, have been resumed in the UK after receiving confirmation from the Health Regulation Authority, “the company reported.

In a statement, Oxford said that vaccine testing was resumed in the UK after pausing on the 6th as a precaution.

An independent committee examined the security measures of the trials, a step that both the multinational and the World Health Organization (WHO) described as routine in these cases.

The committee “has concluded its investigations and has confirmed to the Authority that the tests are safe“AstraZeneca added.

This company’s vaccine is one of the nine that is currently being tested in the world on a massive scale with human beings, which is known as Phase 3.

It is considered one of the most advanced developed worldwide, it is in the final stages of clinical trials before receiving authorization from regulatory bodies to proceed to immunize the population.

This week, the American newspaper The New York Times reported that one of the volunteers had suffered adverse myelitis, a disease in the spinal cord that can be caused by viral infections.

The AstraZeneca laboratory, at the forefront with the university in the development of the vaccine, issued a statement in which it did not confirm that myelitis was the adverse effect.

According to local spokesmen told Clarín, these are journalistic versions. They also clarified that the study was not discontinued rather, the laboratory “made a voluntary pause”, as “is normal” in tests of this type to make an evaluation of the case.

They also reported that this measure it was not requested by any health authority rather, AstraZeneca made the decision to “respect all safety standards“.

The official statement, issued by the company globally, was in the same vein. They noted that “as part of the ongoing randomized controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been activated that has led to the voluntary pause of vaccination in all trials to allow an independent committee to review the safety data for a single unexplained illness event that occurred in the UK phase III trial. “

He also remarks that “this is a routine action that should happen whenever there is a potentially unexplained illness in one of the trials.”

As the company explained, “In large clinical trials, diseases will happen by chance and must be reviewed independently.

The potential vaccine, which showed promising results in early trials, is undergoing clinical trials in the United Kingdom, the United States, Brazil and South Africa.

Last month, the governments of Argentina and Mexico, as well as the Mexican Slim Foundation, reached an agreement with AstraZeneca and the University of Oxford to manufacture the vaccine for their countries and then distribute it to the rest of Latin America, except Brazil.


Related Articles